Serious adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Postoperative atelectasis original authors’ definitions · adult participants undergoing cardiac and major abdominal surgery
Preoperative inspiratory muscle training may leads to lower postoperative atelectasis original authors’ definitions compared with usual care, non‐exercise intervention (low certainty).
1 finding from 1 review
Postoperative pneumonia original authors’ definitions · adult participants undergoing cardiac and major abdominal surgery
Preoperative inspiratory muscle training probably leads to lower postoperative pneumonia original authors’ definitions compared with usual care, non‐exercise intervention (moderate certainty).
1 finding from 1 review
Mechanical ventilation > 48 hours · adult participants undergoing cardiac and major abdominal surgery
It is very uncertain whether preoperative inspiratory muscle training changes mechanical ventilation > 48 hours compared with usual care, non‐exercise intervention (very low certainty).
1 finding from 1 review
Mortality In the early postoperative period (≤ 30 days) · adult participants undergoing cardiac and major abdominal surgery
It is very uncertain whether preoperative inspiratory muscle training changes all‐cause mortality within 30 days during postoperative period compared with usual care, non‐exercise intervention (very low certainty).
1 finding from 1 review
Adverse events · adult participants undergoing cardiac and major abdominal surgery
1 finding from 1 review
Length of hospital stay · adult participants undergoing cardiac and major abdominal surgery
1 finding from 1 review
Sexual satisfaction · Men with COPD
1 finding from 1 review
Effect on later sexual function · Men with COPD
1 finding from 1 review
Adverse events (all cause) · Men with COPD
Testosterone therapy showed no clear difference in adverse events (all cause) compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Exercise capacity (5‐ or 6‐minute walking distance on cylinder air) · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
1 finding from 1 review
Intervention not reported
Mortality · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life (dyspnoea) Measured on the CRQ, the output is a number from 0 to 7, where higher on the scale is better. MID is 0.5. · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention probably leads to higher quality of life (dyspnoea) Measured on the CRQ, the output is a… (moderate certainty).
1 finding from 1 review
Intervention not reported
Dyspnoea · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
1 finding from 1 review
Intervention not reported
Adverse events · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention showed no clear difference in adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalisations · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
1 finding from 1 review
Treatment failure Need to intensify therapy/ED or hospital admission · exacerbations of COPD
Systemic corticosteroid leads to lower treatment failure Need to intensify therapy/ED or hospital admission compared with placebo (high certainty).
1 finding from 1 review
Mortality after discharge (1‐3 months) · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review